

**In the Claims**

1. (Currently Amended) A method of treating a viral infection, the method comprising administering to an individual an effective amount of IFN- $\alpha$  and an effective amount of IFN- $\gamma$ , and co-administering an amount of a ~~non-pirfenidone/pirfenidone~~ non-pirfenidone or non-pirfenidone analog agent effective to reduce or eliminate the occurrence or severity of side effects that would normally be associated with the administration of IFN- $\alpha$  and IFN- $\gamma$ .

2. (Original) The method of claim 1, wherein the individual has been exposed to a virus, and the IFN- $\gamma$  and the IFN- $\alpha$  are administered within 24 hours of exposure to the virus.

3. (Original) The method of claim 1, wherein the individual has been exposed to a virus, and the IFN- $\gamma$  and the IFN- $\alpha$  are administered within 48 hours of exposure to the virus.

4. (Original) The method of claim 1, wherein the individual has been exposed to a virus, and the IFN- $\gamma$  and the IFN- $\alpha$  are administered 72 hours to 35 days after exposure to the virus.

5. (Original) The method of claim 1, wherein the IFN- $\gamma$  and the IFN- $\alpha$  are administered subcutaneously.

6. (Original) The method of any one of claims 1-5, further comprising administering an effective amount of a nucleotide analog or a nucleoside analog.

7. (Original) The method of any one of claims 1-5, wherein the IFN- $\alpha$  is a consensus interferon.

8. (Currently Amended) A method of treating a viral infection, the method comprising administering to an individual an effective amount of IFN- $\alpha$  and an effective amount of IFN- $\gamma$ , and co-administering an amount of a ~~non-pirfenidone/pirfenidone~~ non-pirfenidone or non-pirfenidone

analog agent effective to reduce or eliminate the occurrence or severity of pain that would normally be associated with the viral infection and/or the administration of IFN- $\alpha$  and IFN- $\gamma$ .

9. (Original) The method of claim 8, wherein the IFN- $\gamma$  and the IFN- $\alpha$  are administered subcutaneously.

10. (Original) The method of any one of claims 8, further comprising administering an effective amount of a nucleotide analog or a nucleoside analog.

11. (Original) The method of any one of claims 8-10, wherein the IFN- $\alpha$  is a consensus interferon.

12. (Currently amended) The method of claim 8, wherein the ~~non-pirfenidone/pirfenidone~~ non-pirfenidone or non-pirfenidone analog agent is a non-narcotic analgesic.

13. (Currently amended) The method of claim 1, wherein the ~~non-pirfenidone/pirfenidone~~ non-pirfenidone or non-pirfenidone analog agent is a non-narcotic analgesic.